Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal <sup>®</sup> ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)

Alice Deschenau, Pascal Melin, Julien Azuar, Benjamin Touchon, Isabelle Vinel-Jacquet, Benoit Trojak, Lisa Blecha, Julien Cabé, Margaux Kosim, Geoffroy Dupeyron, Jean-Pierre Daulouède, Georges Brousse, Mathieu Chappuy, Benjamin Rolland

Open source

DOI: 10.1177/29767342261433342
Published: 2026-05-14
Container: Substance Use & Addiction Journal
Publisher: SAGE Publications
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/29767342261433342,
  title = {Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal
                    <sup>®</sup>
                    ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)},
  author = {Alice Deschenau and Pascal Melin and Julien Azuar and Benjamin Touchon and Isabelle Vinel-Jacquet and Benoit Trojak and Lisa Blecha and Julien Cabé and Margaux Kosim and Geoffroy Dupeyron and Jean-Pierre Daulouède and Georges Brousse and Mathieu Chappuy and Benjamin Rolland},
  year = {2026},
  journal = {Substance Use \&amp; Addiction Journal},
  doi = {10.1177/29767342261433342},
  url = {https://doi.org/10.1177/29767342261433342}
}

RIS

TY  - JOUR
TI  - Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal
                    <sup>®</sup>
                    ) in France: A National Retrospective Cross-Sectional Study (OPALE 2)
AU  - Alice Deschenau
AU  - Pascal Melin
AU  - Julien Azuar
AU  - Benjamin Touchon
AU  - Isabelle Vinel-Jacquet
AU  - Benoit Trojak
AU  - Lisa Blecha
AU  - Julien Cabé
AU  - Margaux Kosim
AU  - Geoffroy Dupeyron
AU  - Jean-Pierre Daulouède
AU  - Georges Brousse
AU  - Mathieu Chappuy
AU  - Benjamin Rolland
PY  - 2026
JO  - Substance Use &amp; Addiction Journal
DO  - 10.1177/29767342261433342
UR  - https://doi.org/10.1177/29767342261433342
ER  -

APA

Deschenau, A., Melin, P., Azuar, J., Touchon, B., Vinel-Jacquet, I., Trojak, B., Blecha, L., Cabé, J., Kosim, M., Dupeyron, G., Daulouède, J., Brousse, G., Chappuy, M., & Rolland, B. (2026). Retention and Other Efficacy Outcomes With Long-Acting Injectable Buprenorphine (Buvidal <sup>®</sup> ) in France: A National Retrospective Cross-Sectional Study (OPALE 2). Substance Use & Addiction Journal. https://doi.org/10.1177/29767342261433342

Source records

crossref · retrieved 2026-09-25T21:56:47.066Z